RGNX Regenxbio Inc

Regenxbio Inc is a biotechnology company. It is engaged in the development, commercialization and licensing of recombinant adeno-associated virus gene therapy.

$40.25  +1.73 (4.49%)
As of 06/24/2021 15:59:57 EST     IEX book   CBOE book


Security Information
Category1:  US Equity
Category2:  Common stocks
Category3:  Small cap
GICS sector:  Health Care
Industry:  Biotechnology
Index country:  USA
Country of incorporation:  USA
IPO date:  09/17/2015
Outstanding shares:  42,509,366
Average volume:  308,049
Market cap:   $1,620,882,126
Current dividend yield:  0.00%
All SEC filings:     SEC Edgar Online
Quarterly filings:   10-Q
Annual filings:      10-K
CUSIP:    75901B107
ISIN:        US75901B1070
Sedol:      BZ0G875
Valuation   (See tab for details)
PE ratio:   -13.49
PB ratio:   2.95
PS ratio:   0.00
Return on equity:   0.00%
Net income %:   0.00%

2021 © Stock Market MBA, Inc. Terms of use | Privacy policy